SK65698A3 - Cyclopeptolides - Google Patents

Cyclopeptolides Download PDF

Info

Publication number
SK65698A3
SK65698A3 SK656-98A SK65698A SK65698A3 SK 65698 A3 SK65698 A3 SK 65698A3 SK 65698 A SK65698 A SK 65698A SK 65698 A3 SK65698 A3 SK 65698A3
Authority
SK
Slovakia
Prior art keywords
formula
compounds
substituted
group
leu
Prior art date
Application number
SK656-98A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Dreyfuss
Theodor Fehr
Carolyn A Foster
Dieter Geyl
Berndt Oberhauser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK65698(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523744.2A external-priority patent/GB9523744D0/en
Priority claimed from GBGB9604406.0A external-priority patent/GB9604406D0/en
Priority claimed from GBGB9613990.2A external-priority patent/GB9613990D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK65698A3 publication Critical patent/SK65698A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
SK656-98A 1995-11-21 1996-11-20 Cyclopeptolides SK65698A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9523744.2A GB9523744D0 (en) 1995-11-21 1995-11-21 Organic compounds
GBGB9604406.0A GB9604406D0 (en) 1996-03-01 1996-03-01 Organic compounds
GBGB9613990.2A GB9613990D0 (en) 1996-07-04 1996-07-04 Organic compounds
PCT/EP1996/005123 WO1997019104A1 (en) 1995-11-21 1996-11-20 Cyclopeptolides

Publications (1)

Publication Number Publication Date
SK65698A3 true SK65698A3 (en) 1998-11-04

Family

ID=27267982

Family Applications (1)

Application Number Title Priority Date Filing Date
SK656-98A SK65698A3 (en) 1995-11-21 1996-11-20 Cyclopeptolides

Country Status (27)

Country Link
US (1) US6011136A (de)
EP (1) EP0866801B1 (de)
JP (1) JP3463691B2 (de)
KR (1) KR19990071533A (de)
CN (1) CN1125079C (de)
AR (1) AR012286A1 (de)
AT (1) ATE240972T1 (de)
AU (1) AU712900B2 (de)
BR (1) BR9611619B1 (de)
CA (1) CA2237157C (de)
CO (1) CO4770985A1 (de)
CZ (1) CZ154998A3 (de)
DE (1) DE69628323T2 (de)
ES (1) ES2200079T3 (de)
HU (1) HUP9903810A3 (de)
IL (1) IL124310A0 (de)
MX (1) MX9804048A (de)
MY (1) MY115877A (de)
NO (1) NO982280D0 (de)
NZ (1) NZ322909A (de)
PE (1) PE22998A1 (de)
PL (1) PL186010B1 (de)
RU (1) RU2171260C2 (de)
SK (1) SK65698A3 (de)
TR (1) TR199800897T2 (de)
TW (1) TW450978B (de)
WO (1) WO1997019104A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034283A2 (en) * 2000-10-27 2002-05-02 Novartis Ag Vegh inhibitors and their use
MXPA06010587A (es) * 2004-03-17 2007-03-29 Chiron Corp Tratamiento de neumonia severa adquirida en comunidad por administracion del inhibidor de la via del factor tisular (tfpi).
JP2021519780A (ja) 2018-03-29 2021-08-12 ケザール ライフ サイエンシズKezar Life Sciences Cdpタンパク質分泌阻害剤
CN118319952B (zh) * 2024-04-09 2024-09-20 青岛西凯生物技术有限公司 一种修复子宫内膜损伤的干细胞制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832059A1 (de) * 1988-09-21 1990-03-29 Howaldtswerke Deutsche Werft Tauchtiefengesteuerte ausblasventil-einrichtung
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
AT396108B (de) * 1991-08-21 1993-06-25 Biochemie Gmbh Neues verfahren und neue zwischenprodukte zur herstellung von 7-aminocephalosporansaeurederivaten
JPH07109299A (ja) * 1993-10-13 1995-04-25 Shionogi & Co Ltd 抗hiv物質ペスタヒビン及びその誘導体
WO1996003430A1 (en) * 1994-07-27 1996-02-08 Sandoz Ltd. Organic compounds
US20040219569A1 (en) * 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method

Also Published As

Publication number Publication date
CA2237157C (en) 2009-04-07
TR199800897T2 (xx) 1998-08-21
NZ322909A (en) 1999-07-29
IL124310A0 (en) 1998-12-06
PE22998A1 (es) 1998-05-12
PL186010B1 (pl) 2003-09-30
JP2000502992A (ja) 2000-03-14
ES2200079T3 (es) 2004-03-01
DE69628323D1 (en) 2003-06-26
HUP9903810A3 (en) 2001-04-28
EP0866801A1 (de) 1998-09-30
CO4770985A1 (es) 1999-04-30
CZ154998A3 (cs) 1998-08-12
AU712900B2 (en) 1999-11-18
BR9611619B1 (pt) 2010-08-10
WO1997019104A1 (en) 1997-05-29
MY115877A (en) 2003-09-30
MX9804048A (es) 1998-09-30
NO982280L (no) 1998-05-19
CA2237157A1 (en) 1997-05-29
US6011136A (en) 2000-01-04
HUP9903810A2 (hu) 2000-04-28
JP3463691B2 (ja) 2003-11-05
CN1125079C (zh) 2003-10-22
AU7694696A (en) 1997-06-11
PL326755A1 (en) 1998-10-26
TW450978B (en) 2001-08-21
CN1202904A (zh) 1998-12-23
RU2171260C2 (ru) 2001-07-27
KR19990071533A (ko) 1999-09-27
BR9611619A (pt) 1999-03-30
ATE240972T1 (de) 2003-06-15
DE69628323T2 (de) 2004-08-19
EP0866801B1 (de) 2003-05-21
AR012286A1 (es) 2000-10-18
NO982280D0 (no) 1998-05-19

Similar Documents

Publication Publication Date Title
KR19990028724A (ko) 마크롤라이드
CZ261493A3 (en) Pharmacologically active compounds, process of their preparation and pharmaceutical preparations in which they are comprised
US6013627A (en) Organic compounds
EP0866801B1 (de) Cyclopeptolide
US5338758A (en) Bicyclic diterpene PAF antagonist compounds
US5789602A (en) Physiologically active substances PF1092A, PF1092B and PF1092C, process for the production thereof, and contraceptives and anticancer drugs containing the same as active ingredients
US4560703A (en) Clavulone derivatives, process for preparing the same, and use of said compounds
JPH05331172A (ja) 生物活性プソイロチンaおよびd、アスペルギルス・フミガタスから得られる新規な代謝産物、その調製方法およびその使用
HK1014011B (en) Cyclopeptolides
JPH09110689A (ja) 静脈細胞接着分子−1の産生阻害剤及びナピラジオマイシンsc
KR20070005345A (ko) 2,5-디히드로-4-알킬-2,5-디옥소퓨란 유도체 및이것의 용도
MXPA98000217A (en) Macroli
EP0812327A1 (de) Ein inhibitor für die proteinphosphatase
WO2002034283A2 (en) Vegh inhibitors and their use